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V/PSPECT has the potential to become a ﬁrst hand tool for diagnosis of pulmonary embolism based on standardized technology
andnew holisticinterpretation criteria. Pretest probability helps clinicianschoose themostappropriate objective test fordiagnosis
or exclusion of PE. Interpretation should also take into account all ventilation and perfusion patterns allowing diagnosis of other
cardiopulmonary diseases than PE. In such contexts, V/PSPECT has excellent sensitivity and speciﬁcity. Nondiagnostic reports are
≤3%. V/PSPECT has no contraindication; it is noninvasive and has very low radiation exposure. Moreover, acquisition time for
V/PSPECT is only 20 minutes. It allows quantiﬁcation of PE extension which has an impact on individual treatment. It is uniquely
useful for followup and research.
1.Introduction
Prior to the development of CT angiography, planar ventila-
tion/perfusion scans were the primary noninvasive method
for diagnosis of pulmonary embolism (PE). However, the
technique suﬀered disrepute since the PIOPED I study
showed that 65% of scans were nondiagnostic [1]. As will
be reviewed below, results from later studies based upon
modern imaging techniques and new holistic principles
(combining clinical information, pretest probability, results
of chest radiograph, and patterns typical of PE or other
diseases) reducethenumber ofnondiagnostic ﬁndings to3%
or less, while sensitivity and speciﬁcity are excellent [2, 3].
Since the early 1980s, the advantage of tomography
over planar imaging for PE detection was indicated [4].
Since then, numerous studies have shown such advantages
of ventilation/perfusion single photon emission computed
tomography (V/PSPECT) over alternative techniques, which
indicated that lung scintigraphy is again appreciated as a ﬁrst
line method for diagnosis of PE.
An important issue is to estimate the clinical probability
for PE before performing imaging tests as is elaborated upon
in the European Guidelines for Lung Scintigraphy [2]a n d
by Mamlouk et al. [5]. The object of this paper is to show
the advantages of V/PSPECT in accordance with the European
Guidelines for V/PSPECT [2, 3]. It will be emphasized that
V/PSPECT gives diagnostic information in other conditions
such as pneumonia, COPD, and left heart failure. The
presentation will focus on basic requirements on diagnostic
methods for PE:
(1) fast procedure,
(2) low radiation dose,
(3) no contraindications,
(4) high diagnostic accuracy and few nondiagnostic
reports,
(5) utility for selection of treatment strategy,
(6) suitability for followup and research.
2.AgentsUsed forImaging ofVentilation
Gases are distributed strictly according to regional ventila-
tion. The only gas that is useful for V/PSPECT is krypton,
81mKr. Its short half life (13s) implies that it disappears2 International Journal of Molecular Imaging
from the alveoli by decay rather than by exhalation. After
some minutes of test gas breathing, when the alveolar con-
centration has approached a steady state reﬂecting alveolar
ventilation, V/PSPECT is performed. The rubidium generator
that delivers 81mKrhas a half life of 4.6h. Limited availability
and high costs prevent a general use of 81mKr.
Inhalation of a radio-aerosol is used in nearly all centers
for ventilation scintigraphy. Aerosol particles are liquid or
solid.Particleslargerthan2µmaredepositedinlargeairways
(hot spots). Smaller particles are deposited by sedimentation
and diﬀusion in small airways and alveoli. Particles smaller
than 1µm are mainly deposited in alveoli by diﬀusion.
Aerosol deposition is modiﬁed by ﬂow pattern. High ﬂow
ratesat forcedbreathingpatternsandturbulentﬂowenhance
particle deposition in airways and augment tendencies to
hot spots in ventilation images, particularly in Chronic
Obstructive Pulmonary Disease (COPD).
The mass median aerodynamic diameter, MMAD,
reﬂects radioactivity carried by each liquid particle. Half of
the radioactivity resides in particles smaller than MMAD
and 50% in larger ones. It is often recommended that the
maximum droplet size inhaled by the patient should not
exceed 2µm. Because of the complex physics behind aerosol
deposition pattern, the performance of a nebuliser must be
clinically tested.
Diethylenetriaminepentaacetic acid labelled with tech-
netium,
99mTc-DTPA, is in general use for ventilation
scintigraphy with liquid aerosols. The size of the water
solvable molecule is 492 Dalton [6]. Therefore,
99mTc-DTPA
diﬀusesthroughthealveolocapillarymembranetotheblood.
In a healthy patient, clearance of
99mTc-DTPA occurs with a
half life of about 70 minutes. Increased clearance, leading to
a shorter half life is observed with alveolar inﬂammation of
anykind,suchasalveolitisofallergicortoxicnatureandeven
in smokers [7–9].
Technegas is an aerosol of extremely small carbon
particles, 0.005–0.2µm, generated in a high temperature
furnace [10–12]. The small particle size implies that they are
distributed in the lungs almost like a gas and are deposited
in alveoli by diﬀusion [13, 14]. Technegas provides images
which are equivalent to those with 81mKr [14–18].
Recently, a head to head study of deposition patterns
using Technegas and
99mTc-DTPA performed in a group
of patients routinely admitted for V/PSPECT and in a group
of patients with known COPD was published [19]. Tech-
negas reduced problems of central airway deposition and
peripheral hotspots. Unevenness of radiotracer deposition
and degree of central deposition were less with Technegas,
particularly in the obstructive patients, Figure 1.I ns o m e
patients, mismatched perfusion defects were only identiﬁed
using Technegas because the marked peripheral unevenness
of
99mTc-DTPA obscured mismatch and thereafter PE might
have been overlooked in COPD patients using
99mTc-DTPA.
In a few patients,
99mTc-DTPA yielded images of poor
quality. It was concluded that Technegas is the superior
radio-aerosol, particularly in patients with obstructive lung
disease. Another advantage of using Technegas is that a few
breaths are suﬃcient to achieve an adequate amount of
activity in the lungs.
Technegas
DTPA
MAA
Figure 1: Frontal slices in patient with COPD. Ventilation study
with DTPA and technegas with corresponding perfusion images.
3.AgentUsed forImaging ofPerfusion
For perfusion scintigraphy, radio-labelled MAA, sized 15–
100µm, is injected intravenously. This causes microem-
bolization of pulmonary capillaries and precapillary arte-
rioles, reﬂecting regional perfusion if at least 60000 par-
ticles are injected [20]. Routinely, about 400000 particles
are injected. As there are over 280 billion pulmonary
capillaries and 300 million precapillary arterioles, only a
small fraction of the pulmonary bed will be obstructed.
Fewer particles might be used in patients with known
pulmonary hypertension oraftersingle lungtransplantation.
4.Howto PerformV/PSPECT
4.1. Image Acquisition. Using a dual head camera, Palmer
et al. developed a fast and eﬃcient clinical method for
V/PSPECT [21]. The total acquisition time is only 20 minutes.
A new algorithm allows calculation of the quotient between
ventilation and perfusion and presentation of V/Pquotient
images for easier diagnosis and quantiﬁcation of PE exten-
sion.
The ventilation study starts with inhalation of 25–
30MBq
99mTc-DTPA or Technegas. Immediately after venti-
lation SPECT, a dose of 100–120MBq
99mTc MAA is given
intravenously for perfusion imaging. During the examina-
tion, the supine patient carefully maintains the position
between ventilation and perfusion acquisitions. Immobiliza-
tion for only 20 minutes is usually well tolerated by patients.
Examination in the supine position is comfortable even for
most of critically ill patients. It is also more convenient for
the staﬀ.
When clearance measurements are required,
99mTc-
D T P Am a yb eu s e d .C l e a r a n c ei st h e nc a l c u l a t e df r o mi n i t i a l
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4.2. Radiation Exposure. The doses of 30MBq and 120MBq
for ventilation and perfusion, respectively, allow excellent
V/PSPECT quality at an eﬀective radiation dose of 1.8mSv
[22].
4.3. Reconstruction and Calculation of V/Pquotient Images.
Iterative reconstruction is performed using ordered subset
expectation maximization (OSEM), for example, with 8
subsets and 2 iterations. In processing the images, the
ventilation background was subtracted from the perfusion
tomograms and a normalized V/P image set calculated,
V/Pquotient.T h ea l g o r i t h m sf o rV /Pquotient were developed by
Palmer et al. and further amended by Bajc et al. [21, 23]. The
main consideration in the creation of V/Pquotient images was
to scale smoothened ventilation and perfusion data sets to
display V/Pquotient in a ﬁxed linear scale allowing separation
of normal regions from those with mismatch (Figure 2).
4.4. Presentation of V/PSPECT. The basic format for V/PSPECT
presentation is displayed slices in frontal, sagittal, and
transversal projections, available on any modern system.
The slices must be accurately aligned so that ventilation
and perfusion slices match each other and can be correctly
compared. It is of value to achieve this acquisition in
one session with maintained b o d yp o s i t i o n .T h i si sa l s oa
prerequisite for the calculation of V/Pquotient images, which
greatly facilitates identiﬁcation and quantiﬁcation of PE.
Volume rendered images, such as “Maximum Intensity
Projection”, are available with almost all SPECT systems,
allowing rotating 3D views. Such displays might be useful,
particularly for quantiﬁcation and followup of PE patients
[24].
4.5. Primary Validation of the V/PSPECT Method. Using
a porcine model based upon 201Tl-marked emboli as a
“gold standard”, Bajc et al. validated the new V/PSPECT
method for diagnosis of PE and conﬁrmed the superior
value of tomography over planar imaging and improved
interobserver agreement of defects on the subsegmental
level [25]. In a following clinical head to head comparison
between planar imaging and V/PSPECT,i tw a ss h o w nt h a t
53% more mismatch points were identiﬁed with V/PSPECT
compared to the planar technique [26]. Similar results
have been found by others [27, 28]. SPECT eliminates
superimposed structures, clarifying the segmental and sub-
segmental nature of perfusion defect caused by PE.
5.InterpretationwithEmphasisonPE
Lung scintigraphy for diagnosis of PE and other diseases
should routinely include ventilation and perfusion studies
[21, 23, 25, 27, 29]. In PE, a perfusion defect is due
to an embolus blocking blood ﬂow. Because there is no
corresponding blockage in the airway, ventilation remains
normal causing a mismatch pattern. The distinction of
whether a given perfusion defects is matched or mismatched
is fundamental. The next step is to characterize the perfusion
defects. Perfusion defects due to blockage of a pulmonary
artery should reﬂect the branching of pulmonary circulation
and its classical segmental anatomy. A segmental defect is
wedge shaped and with its base on the pleura as will be
illustrated (Figure 3).
The European guidelines [2, 3] advocate the new holistic
interpretation and reporting of lung SPECT. Freeman et al.
argued that “the expert’s successful interpretation of lung
scans exceeds the best accuracy achievable by algorithms,
which, by deﬁnition, are distillations of decision making into
ﬁnite linear steps. The subjective of the whole is superior to
any possible attempt to deﬁne its discrete parts” [30].
A holistic interpretation of V/PSPECT images includes (1)
clinical information and pretest probability for PE, (2) chest
X-ray when available, (3) recognition of patterns typical for
PE based upon segmental charts, and (4) recognition of
patternsofotherdiseasesthanPEwheneverpossible[21,23].
This is as important as the imaging technique. The
clinician can only beneﬁt from reports, which clearly express
the presence or absence of PE. This goal was not reached
with previous probabilistic reporting methods according to
PIOPED or modiﬁed PIOPED, which deﬁed how planar
scans are reported [1, 31]. Large V/PSPECT studies show
that this is achievable if all patterns representing ventilation
together with perfusion are considered [23, 32–34]. Conclu-
sive reports were given in 97 to 99% of studies.
Recommended criteria for reading V/PSPECT with respect
to acute PE described in the European Guidelines are as
follows.
No PE is reported if there are any of the following
features:
(i) normal perfusion pattern conforming to the
anatomic boundaries of the lungs,
(ii) matched or reversed mismatch V/P defects of any
size, shape, or number in the absence of mismatch,
(iii) mismatch that does not have a lobar, segmental or
subsegmental pattern.
PE is reported if there is
(i) V/P mismatch of at least one segment or two sub-
segments that conforms to the pulmonary vascular
anatomy.
Nondiagnostic for PE is reported if there are
(i) multiple V/P abnormalities not typical of speciﬁc
diseases.
In PE, it is fundamental that mismatched areas are conical
with the base of the cone along the pleura and conform
to known sub-segmental and segmental vascular anatomy.
With such interpretation criteria, recent V/PSPECT studies
in over 3000 cases showed according to a recent review a
negative predictive value of 97–99%, a sensitivity of 96–
99%, and a speciﬁcity of 91–98% for PE [3] .T h er a t eo f
nondiagnostic ﬁndings was 1–3% [23, 32–34]. Using our
technique, V/PSPECT yields ventilation and perfusion images
in exactly the same projections. This makes calculation
of V/Pquotient images possible and facilitates recognition of
mismatch, particularly important in the middle lobe and4 International Journal of Molecular Imaging
Ventilation
Perfusion
V/Pquotient
Figure 2: Frontal slices in patient with massive PE. Absent
perfusion in the right lung and sub-segmental defects in the left are
clearly delineated in V/Pquotient images.
lingula where mismatch may be overlooked if the lung is not
accurately delineated by its ventilation images [35].
V/PSPECT is the method of choice for quantiﬁcation of
the extent of embolism, because all emboli in the whole
lung are recognised and it has greater sensitivity compared
to MDCT [27, 32, 33]. The number of segments and sub-
segments indicating for PE typical mismatch are counted
and expressed in % of the total lung parenchyma [24].
A segmental reduction or a sub-segmental total deﬁciency
of function is attributed 1 point, and a segmental total
deﬁciency is attributed 2 points. Therefore, the 9 segments
of each lung can be represented by the total of 18 points.
Mismatch defects are expressed as mismatch points, which
after division by 36 give the fraction of the lung that is
embolized. The reduction in total overall lung function can
be estimated by adding the number of regions with reduced
ventilation and/or perfusion.
Patients with up 40% PE could be safely treated at home
if ventilation abnormalities engaged not more that 20%
of the lung. Since 2004, the University Hospital of Lund
has safely treated about 60% of patients with PE at home
(approximately 1500).
6.Diagnosisof PulmonaryEmbolism
V/PSPECT images allow clear identiﬁcation of segmental
and sub-segmental perfusion defects, as in Figure 2 from a
woman with extensive PE.
Figure 3 shows a well-delineated segmental perfusion
defect. Followup after three days showed an almost normal
pattern, conﬁrming the diagnosis of PE.
Importantly, mismatch ﬁndings without a segmental
character do not indicate PE. Such ﬁndings are often
Ventilation
Perfusion
Initially 3 days later
V/Pquotient
Figure 3: Sagittal slice in patient with segmental PE. Perfusion
defect in anterior segment initially, nicely delineated in V/Pquotient
image. After 3 days, resolution is observed.
observed in patients with heart failure, mediastinal adenopa-
thy, postradiation therapy, and so forth.
6.1. Indications for V/PSPECT
6.1.1.Diagnostic AccuracyandMethodologicalConsiderations.
The clinical value of V/PSPECT has been conﬁrmed in several
studies [27, 29, 32–34]. This has been highlighted by Stein
et al. in a recent review [36]. V/PSPECT is today the method
recommended by the European Association of Nuclear
Medicine for clinical diagnosis, followup, and research [2].
6.1.2. Selection of Therapeutic Strategy. Management of PE
was previously conﬁned to in-hospital therapy, using throm-
bolysis or heparin injections followed by oral anticoagulants
for extended periods of time.
V/PSPECT allows objective quantiﬁcation of PE. It has
been shown that out-patient treatment is safe when based
upon V/PSPECT that quantiﬁes PE extension and identiﬁes
V/P defects of other etiologies [24]. V/PSPECT is accordingly
a tool to guide the individual treatment.
6.1.3. Followup. For followup, V/PSPECT is the method
recommended by the European Association of Nuclear
medicine due to its high sensitivity, noninvasiveness, low
radiation exposure, and absence of contraindications [2].
Clinical reasons for followup are
(i) persistent V/P mismatches often occur after PE;
(ii) PE may recur in identical locations;
(iii) a prior study will help determine the age of a new
defect;
( i v )T h e r ei sa ni m p a c to nt h e r a p yd e c i s i o n .International Journal of Molecular Imaging 5
Ventilation
Perfusion
V/Pquotient
Figure 4: Patient with COPD and extensive PE. On frontal
slices, uneven ventilation with peripheral hot spots is observed,
and perfusion images showed multiple perfusion defects, clearly
delineated on VPquotient images.
Obviously, evaluation of diﬀerent drugs and treatment
strategies merits the use of V/PSPECT because of its high
sensitivity and quality with regards to quantiﬁcation.
7.AdditionalFindings
V/PSPECT a l l o w sd i a g n o s i so fs e v e r a lo t h e rd i s e a s e sw h i c h
have diﬀerent scintigraphic appearances to PE, as detailed
below [2, 3, 37].
7.1. Chronic Obstructive Pulmonary Disease (COPD). In
COPD matched areas with defects in ventilation and per-
fusion are observed. Ventilation defects are commonly more
prominent than those of perfusion which leads to a pattern
called reverse mismatch [19]. V/PSPECT frequently provides
the ﬁrst indication of COPD. Notably, V/PSPECT allows the
diagnosis of PE even in the presence of COPD [32, 37],
Figure 4.
7.2. Heart Failure. In left heart failure, redistribution of
perfusion towards upper lung regions is well recognised
since long [38]. Ventilation is usually not aﬀected to the
same degree as perfusion, which leads to a mismatch
pattern. Importantly, this pattern does not conform to
segmental anatomy of pulmonary arteries and it is not of a
segmental character. Among patients referred for suspected
PE, redistribution of perfusion to upper ventral regions
indicated heart failure in 15% of cases [39]. The positive
predictive value of the referred V/PSPECT pattern was 88%.
Figure 5 shows V/PSPECT before and after treatment for heart
failure.
7.3. Pneumonia. Pneumonic regions lack ventilation while
perfusion may partlybe upheld.The mostfrequent ﬁnding is
Ventilation
Perfusion
Initial 10 days later
V/Pquotient
Figure 5: Patient with heart failure. Sagittal slice on the left
panel shows redistribution of perfusion towards anterior region;
ventilation is less aﬀected causing mismatch of non-segmental
character. Right panel shows control after 10 days of treatment
with normalization of ventilation and perfusion distribution but
with new ventilation and perfusion defect in upper lobe due to
pneumonia.
am a t c h e dd e f e c t[ 40]. In case of partly preserved perfusion,
reversed mismatch is observed [40, 41]. Preserved perfusion
along the pleural border leads to a “stripe sign” [42, 43].
V/PSPECT frequently shows this sign because no overlaying
structures obscure the images, Figure 6.
The combination of PE and pneumonia is common [32].
Suspicion or knowledge that a patient has pneumonia does
not contraindicate V/PSPECT.O nt h ec o n t r a r y ,V /PSPECT may
be life-saving in the most complex cases [44].
8.ConcludingRemarks
The qualities of V/PSPECT rely upon adequate and stan-
dardized technology of combined ventilation and perfusion
studies as well as new holistic interpretation criteria as
discussed.
V/PSPECT has excellent sensitivity and speciﬁcity.The rate
of nondiagnostic reports is ≤3%. V/PSPECT is noninvasive
and can be performed in all patients. The radiation exposure
is low. With eﬃcient technique and eﬀective organization,
V/PSPECT acquisition time is only 20 minutes. Furthermore,
it allows quantiﬁcation of PE that in some centres has
impact on choice of treatment. V/PSPECT is uniquely useful
for followup and research. Its outstanding qualities merit
consideration ofits use as theprimary diagnostic method for
PE in all hospitals in which nuclear medicine is practiced.
V/PSPECT frequently gives diagnosis of both PE as well
as comorbid conditions as COPD, left heart failure, and
pneumonia.6 International Journal of Molecular Imaging
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Ventilation
V/Pquotient
Figure 6: Patient with extensive pneumonia. Sagittal slices in a
79-year-old man who felt general illness, shivering, and low blood
pressure. Chest X-ray was interpreted as pleural eﬀusion. The
ventilation study of the left lung showed almost absent ventilation,
while perfusion was mainlypreserved, and a stripe sign is observed.
Diagnosis with V/PSPECT was bilateral pneumonia, and this was
conﬁrmed later at autopsy.
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